| Project/Area Number |
26462473
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Iwate Medical University (2016)
Akita University (2014-2015) |
|---|
Principal Investigator |
KUMAGAI JIN 岩手医科大学, 医学部, 教授 (60333936)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
寺田 幸弘 秋田大学, 医学(系)研究科(研究院), 教授 (10260431)
宇都宮 裕貴 東北大学, 大学病院, 准教授 (10359507)
佐藤 直樹 秋田大学, 医学(系)研究科(研究院), 准教授 (40447199)
白澤 弘光 秋田大学, 医学部, 医員 (60598019)
佐藤 亘 秋田大学, 医学部, 助教 (10726441)
椛嶋 克哉 秋田大学, 医学部, 技術系補佐員 (30615422)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 卵子 / 蛍光免疫染色 / 卵子の輸送 / 電界撹拌 / ヒト卵子 / 体外培養 / 体癌患者 / 電界撹拌法 / 卵子輸送 / 加齢 / 卵巣 / 紡錘体 / 核移植 |
|---|
| Outline of Final Research Achievements |
Using non-contact alternating-current electric-field mixing of microdroplets, we developed the economical fluorescence immunostaining of the human ovum with time efficiency. We could stain the mouse ovum by this method using the anti-tubulin antibody which was the first antibody by 16,000 times dilution that 80 times as large as recommended dilution and could shorten discrimination time until five minutes. It is expected the saving precious antibodies and shortening the staining time in a future study.
On the other hand, concerning the human ovum transportation, in vitro maturation rate of human ovum significantly decreased in the immature ovum transportation case of 250km between Akita and Sendai, but improved it by stabilizing a vapor phase using a cell porter in a transportation container. This result is expected to bring the application to the ovum freeze of women with malignant tumor.
|
